Stemtech Corporation (STEK)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Stem Cell Enhancers	4.92M	Log In	Log In
Stem Cell Enhancers Growth	7.94%	Log In	Log In

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Latin America	3.07M	Log In	Log In
Latin America Growth	22.54%	Log In	Log In
United States and Canada	1.68M	Log In	Log In
United States and Canada Growth	8.33%	Log In	Log In
Asia	180.27K	Log In	Log In
Asia Growth	-64.72%	Log In	Log In